Revvity (RVTY) Stock Price, Fundamentals & Analysis

What RVTY does

Revvity (RVTY) is a US stock in the Healthcare sector, specifically the Diagnostics & Research industry, headquartered in Waltham, United States. The company provides health sciences solutions, technologies, and services, including instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training, and services. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, and it develops technologies supporting genomic workflows for oncology, immunodiagnostics, and drug discovery.

Key numbers explained

• 142.11 USD is the current price, representing the last traded value of one share.
• The trailing P/E ratio of 68.3 compares the share price to the last 12 months of earnings per share (2.08 USD), showing how much investors pay for each dollar of recent earnings.
• The forward P/E ratio of 24.1 uses expected future earnings, offering a view of valuation based on what analysts anticipate.
• 15.86B USD is the market capitalization, the total value of all outstanding shares.
• The dividend yield of 0.2% indicates the annual dividend as a percentage of the share price; the ex-dividend date is 23 Oct 2026, and 13% of earnings are paid out as dividends.
• Beta of 1.09 suggests the stock's price tends to move slightly more than the overall market.
• The 52-week range of 81.22 – 149.52 shows the lowest and highest prices over the past year, with a 69.6% increase over that period.
• Revenue of 2.91B USD with 1.3% year-over-year growth and a profit margin of 8.2% show the company's scale and efficiency.

Recent news

Headlines include questions about whether Revvity is outperforming the Dow and why the stock is getting attention today. Other articles discuss how Revvity is positioned alongside peers like Danaher, Sartorius, Agilent, Bruker, Thermo Fisher Scientific, and Yokogawa in markets such as label-free detection and high content screening. Goldman Sachs adjusted its price target on Revvity to 140 from 100, keeping a Neutral rating.

What to watch

For a stock like Revvity, investors typically monitor earnings reports, with the next one scheduled for 26 Oct 2026. The healthcare and diagnostics sectors are influenced by regulatory changes, research funding, and technological shifts in genomic and detection technologies. Broader market movements, interest rates, and the performance of peers such as Pfizer (PFE), Edwards Lifesciences (EW), and Veeva Systems (VEEV) can also affect sentiment.